drugset / Trial / NCT00120120

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy

NCT00120120

Phase 2/3 Completed 181 enrolled Celgene Corporation
RandomizedSingle-groupQuadruple-blindTreatment

Summary

The purpose of this multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of lenalidomide in the treatment of painful lumbar radiculopathy.

Timeline

Start
2005-01
Primary completion
2007-10
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenalidomide Other / unclassified 2 mg Oral
Subject Lenalidomide Other / unclassified 5 mg Oral

Indications